Advertisement

Neurotherapeutics

, Volume 16, Issue 3, pp 858–867 | Cite as

A Longitudinal Study of the Neurologic Safety of Acute Baclofen Use After Spinal Cord Injury

  • Jacquelyn J. CraggEmail author
  • Bobo Tong
  • Catherine R. Jutzeler
  • Freda M. Warner
  • Neil Cashman
  • Fred Geisler
  • John L. K. Kramer
Original Article

Abstract

The objective of our study was to determine whether treatment with baclofen is neurologically safe with respect to exposure during recovery from spinal cord injury. We performed a secondary longitudinal analysis of a cohort of adult patients with traumatic acute spinal cord injury. Cumulative baclofen dose was computed over the first 4 weeks following injury from concomitant medication information from a completed clinical trial. The main outcome measure was neurologic status, which was assessed over 52 weeks with “marked recovery” defined as the conversion to higher sensory and motor function. To complete the drug safety profile, drug toxicity was assessed with assays from standard blood work. Multivariable Cox regression was used to compute hazard ratios (HRs) and 95% confidence intervals (CIs). Of the cohort (n = 651), 18% (n = 115) received baclofen within 4 weeks post injury. Baclofen use was associated with higher rates of marked neurologic recovery, even after adjustment for injury severity (HR = 2.1, 95% CI 1.5–3.0 for high dose vs none). Baclofen exposure was not associated with liver or renal side effects. The use of other medications indicated for spasticity was not associated with neurological outcomes. Overall, this longitudinal analysis provides level 3 evidence on the neurologic safety of baclofen and potential beneficial effects on recovery in the early days after acute traumatic spinal cord injury. The usefulness of concomitant medication files from completed clinical trials is highlighted. We also highlight the importance of incorporating logical patient questions and neurological outcomes into research addressing drug safety.

Keywords

spinal cord injury baclofen anti-spasticity drug safety patient-oriented research 

Notes

Acknowledgments

Dr. Cragg is supported by the Society in Science—Branco Weiss Postdoctoral Fellowship and the Michael Smith Foundation for Health Research (MSFHR). Dr. Kramer is supported by a Scholar Award from the MSFHR and Rick Hansen Institute, as well as the Canadian Institutes of Health Research, ERA-NET NEURON, Wings for Life, and the International Foundation for Research in Paraplegia (IRP). Dr. Jutzeler is supported by the IRP and is a Craig H. Nielsen Foundation postdoctoral fellow. Ms. Warner is supported by the University of British Columbia Four Year Fellowship.

Required Author Forms

Disclosure forms provided by the authors are available with the online version of this article.

Author Contributions

JJC was responsible for the design and conceptualization of the study, data analyses, and drafting the manuscript. BT was responsible for data cleaning, data analyses, and drafting the manuscript. CRJ, FMW, and NC were responsible for interpretation of data and revising the manuscript for intellectual content. FG was responsible for primary data collection, interpretation of data, and revising the manuscript for intellectual content. JLK was responsible for study concept/design, interpretation of data, and revising the manuscript for intellectual content.

Compliance with Ethical Standards

Approval for this study (secondary analysis) was received by an institutional ethical standards committee on human experimentation at the University of British Columbia.

Disclosures

All authors report no disclosures.

References

  1. 1.
    Tator CH (1995) Update on the Pathophysiology and Pathology of Acute Spinal Cord Injury. Brain Pathol 5:407–413.  https://doi.org/10.1111/j.1750-3639.1995.tb00619.x CrossRefPubMedGoogle Scholar
  2. 2.
    Krueger H, Noonan VK, Trenaman LM, et al (2013) The economic burden of traumatic spinal cord injury in Canada. Chronic Dis Inj Can 33:113–122PubMedGoogle Scholar
  3. 3.
    Noonan VK, Fingas M, Farry A, et al (2012) Incidence and Prevalence of Spinal Cord Injury in Canada: A National Perspective. Neuroepidemiology 38:219–226.  https://doi.org/10.1159/000336014 CrossRefPubMedGoogle Scholar
  4. 4.
    Elbasiouny SM, Moroz D, Bakr MM, Mushahwar VK (2010) Management of Spasticity After Spinal Cord Injury: Current Techniques and Future Directions. Neurorehabil Neural Repair 24:23–33.  https://doi.org/10.1177/1545968309343213 CrossRefPubMedGoogle Scholar
  5. 5.
    Adams M, Hicks A (2005) Spasticity after spinal cord injury. Spinal Cord 43:577–586.  https://doi.org/10.1038/sj.sc.3101757 CrossRefPubMedGoogle Scholar
  6. 6.
    Kwon BK, Tetzlaff W, Grauer JN, et al (2004) Pathophysiology and pharmacologic treatment of acute spinal cord injury. Spine J 4:451–64.  https://doi.org/10.1016/j.spinee.2003.07.007 CrossRefPubMedGoogle Scholar
  7. 7.
    Tator CH, Fehlings MG (1991) Review of the secondary injury theory of acute spinal cord trauma with emphasis on vascular mechanisms. J Neurosurg 75:15–26.  https://doi.org/10.3171/jns.1991.75.1.0015 CrossRefPubMedPubMedCentralGoogle Scholar
  8. 8.
    Belegu V, Oudega M, Gary DS, McDonald JW (2007) Restoring Function After Spinal Cord Injury: Promoting Spontaneous Regeneration with Stem Cells and Activity-Based Therapies. Neurosurg. Clin. N. Am. 18:143–168CrossRefPubMedGoogle Scholar
  9. 9.
    McDonald JW, Sadowsky CL, Stampas A (2012) The changing field of rehabilitation: Optimizing spontaneous regeneration and functional recovery. Handb Clin Neurol 109:317–336.  https://doi.org/10.1016/B978-0-444-52137-8.00020-6 CrossRefPubMedGoogle Scholar
  10. 10.
    Yelnik AP, Simon O, Bensmail D, et al (2009) Drug treatments for spasticity. Ann Phys Rehabil Med 52:746–756.  https://doi.org/10.1016/j.rehab.2009.09.005 CrossRefPubMedGoogle Scholar
  11. 11.
    Dr. Wise Young - Baclofen Question. http://sci.rutgers.edu/forum/showthread.php?133388-Dr-Wise-Young-Baclofen-Question. Accessed 6 Apr 2018
  12. 12.
  13. 13.
    Geisler FH, Coleman WP, Grieco G, et al (2001) The Sygen multicenter acute spinal cord injury study. Spine (Phila Pa 1976) 26:S87–98CrossRefGoogle Scholar
  14. 14.
    Geisler FH, Coleman WP, Grieco G, et al (2001) Recruitment and early treatment in a multicenter study of acute spinal cord injury. Spine (Phila Pa 1976) 26:S58–67CrossRefGoogle Scholar
  15. 15.
    Hadley MN, Walters BC (2013) Introduction to the Guidelines for the Management of Acute Cervical Spine and Spinal Cord Injuries. Neurosurgery 72:5–16.  https://doi.org/10.1227/NEU.0b013e3182773549 CrossRefPubMedGoogle Scholar
  16. 16.
    Hadley MN, Walters BC, Grabb PA, et al (2002) Guidelines for the management of acute cervical spine and spinal cord injuries. Clin. Neurosurg. 49:407–498PubMedGoogle Scholar
  17. 17.
    Geisler FH, Coleman WP, Grieco G, et al (2001) Measurements and recovery patterns in a multicenter study of acute spinal cord injury. Spine (Phila Pa 1976) 26:S68–86CrossRefGoogle Scholar
  18. 18.
    Fawcett JW, Curt A, Steeves JD, et al (2007) Guidelines for the conduct of clinical trials for spinal cord injury as developed by the ICCP panel: spontaneous recovery after spinal cord injury and statistical power needed for therapeutic clinical trials. Spinal Cord 45:190–205.  https://doi.org/10.1038/sj.sc.3102007 CrossRefPubMedGoogle Scholar
  19. 19.
    Steeves JD, Kramer JK, Fawcett JW, et al (2011) Extent of spontaneous motor recovery after traumatic cervical sensorimotor complete spinal cord injury. Spinal Cord 49:257–65.  https://doi.org/10.1038/sc.2010.99 CrossRefPubMedGoogle Scholar
  20. 20.
    Kirshblum SC, Burns SP, Biering-Sorensen F, et al (2011) International standards for neurological classification of spinal cord injury (revised 2011). J Spinal Cord Med 34:535–46.  https://doi.org/10.1179/204577211X13207446293695 CrossRefPubMedPubMedCentralGoogle Scholar
  21. 21.
    Albumin: Reference Range, Interpretation, Collection and Panels. https://emedicine.medscape.com/article/2054430-overview. Accessed 6 Apr 2018
  22. 22.
  23. 23.
    Hepatitis C, Liver Enzyme Levels | Hepatitis Central. http://www.hepatitiscentral.com/hcv/labs/liverenzymes/. Accessed 6 Apr 2018
  24. 24.
    Hyperphosphatemia (High Phosphate) - Managing Side Effects - Chemocare. http://chemocare.com/chemotherapy/side-effects/hyperphosphatemia-high-phosphate.aspx. Accessed 6 Apr 2018
  25. 25.
    Blood urea nitrogen (BUN) test - About - Mayo Clinic. https://www.mayoclinic.org/tests-procedures/blood-urea-nitrogen/about/pac-20384821. Accessed 6 Apr 2018
  26. 26.
    Bilirubin blood test Information | Mount Sinai - New York. http://www.mountsinai.org/health-library/tests/bilirubin-blood-test. Accessed 6 Apr 2018
  27. 27.
    What Is a Creatinine Blood Test? Symptoms, Low & High Ranges. https://www.medicinenet.com/creatinine_blood_test/article.htm. Accessed 6 Apr 2018
  28. 28.
    Domingo A, Al-Yahya AA, Asiri Y, et al (2012) A Systematic Review of the Effects of Pharmacological Agents on Walking Function in People with Spinal Cord Injury. J Neurotrauma 29:865–879.  https://doi.org/10.1089/neu.2011.2052 CrossRefPubMedPubMedCentralGoogle Scholar
  29. 29.
    Dario A, Scamoni C, Bono G, et al (2001) Functional improvement in patients with severe spinal spasticity treated with chronic intrathecal baclofen infusion. Funct Neurol 16:311–5PubMedGoogle Scholar
  30. 30.
    Azouvi P, Mane M, Thiebaut JB, et al (1996) Intrathecal baclofen administration for control of severe spinal spasticity: Functional improvement and long-term follow-up. Arch Phys Med Rehabil 77:35–39.  https://doi.org/10.1016/S0003-9993(96)90217-8 CrossRefPubMedGoogle Scholar
  31. 31.
    Norman KE, Pepin A, Barbeau H (1998) Effects of drugs on walking after spinal cord injury. Spinal Cord 36:699–715CrossRefPubMedGoogle Scholar
  32. 32.
    Theriault ER, Huang V, Whiteneck G, et al (2016) Antispasmodic medications may be associated with reduced recovery during inpatient rehabilitation after traumatic spinal cord injury. J Spinal Cord Med 00:1–9.  https://doi.org/10.1080/10790268.2016.1245010 CrossRefGoogle Scholar
  33. 33.
    Psaty BM, Siscovick DS (2010) Minimizing Bias Due to Confounding by Indication in Comparative Effectiveness Research. JAMA 304:897.  https://doi.org/10.1001/jama.2010.1205 CrossRefPubMedGoogle Scholar
  34. 34.
    Green AR, Hainsworth AH, Jackson DM (2000) GABA potentiation: a logical pharmacological approach for the treatment of acute ischaemic stroke. Neuropharmacology 39:1483–94CrossRefPubMedGoogle Scholar
  35. 35.
    Costa C, Leone G, Saulle E, et al (2004) Coactivation of GABAA and GABAB Receptor Results in Neuroprotection during In Vitro Ischemia. Stroke 35:596–600.  https://doi.org/10.1161/01.STR.0000113691.32026.06 CrossRefPubMedGoogle Scholar
  36. 36.
    Chumakov I, Milet A, Cholet N, et al (2014) Polytherapy with a combination of three repurposed drugs (PXT3003) down-regulates Pmp22 over-expression and improves myelination, axonal and functional parameters in models of CMT1A neuropathy. Orphanet J Rare Dis 9.  https://doi.org/10.1186/s13023-014-0201-x
  37. 37.
    Fern R, Waxman SG, Ransom BR (1995) Endogenous GABA attenuates CNS white matter dysfunction following anoxia. J Neurosci 15:699–708CrossRefPubMedGoogle Scholar
  38. 38.
    Luyt K, Slade TP, Dorward JJ, et al (2007) Developing oligodendrocytes express functional GABAB receptors that stimulate cell proliferation and migration. J Neurochem 100:822–840.  https://doi.org/10.1111/j.1471-4159.2006.04255.x CrossRefPubMedGoogle Scholar
  39. 39.
    Magnaghi V, Ballabio M, Cavarretta IT, et al (2004) GABAB receptors in Schwann cells influence proliferation and myelin protein expression. Eur J Neurosci 19:2641–2649.  https://doi.org/10.1111/j.0953-816X.2004.03368.x CrossRefPubMedGoogle Scholar
  40. 40.
    Barker C (2010) Exploratory method for summarizing concomitant medication data - The mean cumulative function. Pharm Stat 9:331–336.  https://doi.org/10.1002/pst.395 CrossRefPubMedGoogle Scholar
  41. 41.
    Warner FM, Cragg JJ, Jutzeler CR, et al (2017) Early Administration of Gabapentinoids Improves Motor Recovery after Human Spinal Cord Injury. Cell Rep 18:1614–1618.  https://doi.org/10.1016/j.celrep.2017.01.048 CrossRefPubMedGoogle Scholar
  42. 42.
    Cragg JJ, Haefeli J, Jutzeler CR, et al (2016) Effects of Pain and Pain Management on Motor Recovery of Spinal Cord-Injured Patients: A Longitudinal Study. Neurorehabil Neural Repair 30:753–61.  https://doi.org/10.1177/1545968315624777 CrossRefPubMedGoogle Scholar
  43. 43.
    Short DJ, El Masry WS, Jones PW (2000) High dose methylprednisolone in the management of acute spinal cord injury - A systematic review from a clinical perspective. Spinal CordGoogle Scholar
  44. 44.
    Drugs.com | Prescription Drug Information, Interactions & Side Effects. https://www.drugs.com/. Accessed 6 Apr 2018
  45. 45.
    Orange Book: Approved Drug Products with Therapeutic Equivalence Evaluations. https://www.accessdata.fda.gov/scripts/Cder/ob/index.cfm. Accessed 6 Apr 2018
  46. 46.
    Baclofen (Baclofen Tablets): Side Effects, Interactions, Warning, Dosage & Uses. https://www.rxlist.com/baclofen-drug.htm#indications_dosage. Accessed 6 Apr 2018
  47. 47.
    Smith C, LaRocca N, Giesser B, Scheinberg L (1991) High-dose oral baclofen: Experience in patients with multiple sclerosis. Neurology 1829–1831Google Scholar
  48. 48.
    Holtz KA, Szefer E, Noonan VK, et al (2018) Treatment patterns of in-patient spasticity medication use after traumatic spinal cord injury: a prospective cohort study. Spinal Cord.  https://doi.org/10.1038/s41393-018-0165-0
  49. 49.
    Black N (1996) Why we need observational studies to evaluate the effectiveness of health care. BMJ 312:1215–8.  https://doi.org/10.1136/bmj.312.7040.1215 CrossRefPubMedPubMedCentralGoogle Scholar
  50. 50.
    Benson K, Hartz AJ (2000) A comparison of observational studies and randomized, controlled trials. N Engl J Med 342:1878–86.  https://doi.org/10.1056/NEJM200006223422506 CrossRefPubMedGoogle Scholar
  51. 51.
    Hernández-Díaz S, McElrath TF, Pennell PB, et al (2017) Fetal growth and premature delivery in pregnant women on antiepileptic drugs. Ann Neurol 82:457–465.  https://doi.org/10.1002/ana.25031 CrossRefPubMedGoogle Scholar
  52. 52.
    Devinsky O, Leppik I, James Willmore L, et al (1995) Safety of intravenous valproate. Ann Neurol 38:670–674.  https://doi.org/10.1002/ana.410380418 CrossRefPubMedGoogle Scholar

Copyright information

© The American Society for Experimental NeuroTherapeutics, Inc. 2019

Authors and Affiliations

  • Jacquelyn J. Cragg
    • 1
    Email author
  • Bobo Tong
    • 1
  • Catherine R. Jutzeler
    • 1
    • 2
  • Freda M. Warner
    • 1
    • 2
  • Neil Cashman
    • 3
  • Fred Geisler
    • 4
  • John L. K. Kramer
    • 1
    • 2
  1. 1.International Collaboration on Repair Discoveries (ICORD)University of British ColumbiaVancouverCanada
  2. 2.School of KinesiologyUniversity of British ColumbiaVancouverCanada
  3. 3.Division of Neurology, Department of Medicine, Faculty of MedicineUniversity of British ColumbiaVancouverCanada
  4. 4.University of SaskatchewanSaskatoonCanada

Personalised recommendations